Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines

A method of regressing pancreatic tumor of a subject, comprising:

• obtaining a liposomal formulation comprising a cationic lipopeptide having formula A, a first co-lipid, a second co-lipid, a pharmaceutically acceptable carrier, and a therapeutic agent, wherein a molar ratio of the cationic lipopeptide having formula A, the first co-lipid, the second co-lipid, the pharmaceutically acceptable carrier, and the therapeutic agent is 0.5:1:0.25:0.02:1-10;
• and
• administering a therapeutically effective amount of the liposomal formulation and an in vivo dendritic cell targeting DNA vaccine comprising a plasmid cytomegalovirus encoding mesothelin (p-CMV-MSLN) to a subject in need thereof via intravenous or subcutaneous injection,
• wherein the formula A is
• where R1 and R2 are each independently selected from hydrogen and a lipophilic moiety containing eight to twenty four carbon atoms selected from the group consisting of alkyl, mono-, di- and tri-unsaturated alkenyl, provided both R1 and R2 are not hydrogen;
• R3 is selected from the group consisting of hydrogen, C1-C5 alkyl, hydroxyl, and C1-C5 amino-alkyl,
• the first and the second co-lipids are 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and cholesterol, respectively,
• the pharmaceutically acceptable carrier is DSPE(SEQ ID NO:
• 6)-(PEG)2000-NH2, and
• the therapeutic agent is selected from the group consisting of curcumin, gemcitabine, and a combination thereof, wherein a weight ratio of curcumin to gemcitabine is 5-20:1-5 in the combination.